| Safety of parathyroid hormone for the treatment of osteoporosis. | |
| | |
MedLine Citation:
|
PMID: 18430395 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are the effects of the registered dose of teriparatide (20 microg/day) on the incidence of hypercalcemia, hypercalciuria, and hyperuricemia, and the US Food and Drug Administration's "black-box" warning regarding osteogenic sarcoma in the rat model. This review discusses these issues and provides the author's extensive clinical experience and advice on the use of teriparatide in clinical practice. |
| | |
Authors:
|
Paul D Miller |
Related Documents
:
|
20151565 - Invisalign and porecelain: the contemporary restorative powerhouse. 18761505 - The sociology of pharmaceuticals: progress and prospects. 1715145 - Scorpion sting: a management problem. 10123855 - Redundancy or retirement? 21841615 - Developing clinical leadership capacity among uk foundation trainees. 12395585 - Striving for sustainable wildlife management: the case of kilombero game controlled are... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current osteoporosis reports Volume: 6 ISSN: 1544-2241 ISO Abbreviation: Curr Osteoporos Rep Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-04-23 Completed Date: 2008-06-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101176492 Medline TA: Curr Osteoporos Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 12-6 Citation Subset: IM |
Affiliation:
|
Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Suite #250, Lakewood, CO 80227, USA. millerccbr@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Bone Density Conservation Agents / adverse effects*, therapeutic use Bone Neoplasms / chemically induced Disease Models, Animal Dose-Response Relationship, Drug Humans Osteoporosis / drug therapy* Osteosarcoma / chemically induced Parathyroid Hormone / adverse effects*, therapeutic use Rats Rats, Inbred F344 Teriparatide / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Parathyroid Hormone; 52232-67-4/Teriparatide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vitamin D therapy.
Next Document: Intravenous zoledronic acid for the treatment of osteoporosis.